Biogen Inc.’s hemophilia business will begin trading on its own as Bioverativ, with the ticker BIVV, starting Thursday. Biogen previously announced the spin-off in May of 2016, and said it would allow Biogen to focus on its neurological treatments. Biogen shares rose 0.8% in pre-market trade Wednesday. Company shares have sunk 1.9% over the last three months, compared with a 7.9% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News